Ryan, B M <br/><br/>
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Apr 2006 
 - 597-604 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>0923-7534 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdj121  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Breast Neoplasms--metabolism<br/>Cohort Studies<br/>Female<br/>Humans<br/>Inhibitor of Apoptosis Proteins<br/>Microtubule-Associated Proteins--metabolism<br/>Neoplasm Proteins--metabolism<br/>Plasminogen Activator Inhibitor 1--metabolism<br/>Receptor, ErbB-2--metabolism<br/>Survivin<br/>Treatment Outcome<br/>Urokinase-Type Plasminogen Activator--metabolism<br/>Vascular Endothelial Growth Factor A--metabolism